Skip to main content
SpringerLink
Log in

Generic Clozapine

A Cost-Saving Alternative to Brand Name Clozapine?

  • Current Opinion
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

As a consequence of its prevalence, early onset and chronicity, schizophrenia imposes clinical and economic impediments to healthcare practitioners and society alike. Among the many antipsychotics available to treat the symptoms of this devastating illness, clozapine has emerged and differentiated itself from the others as the agent most efficacious for the treatment of refractory patients.

Since the patent for Clozaril®1 (Novartis) expired in 1998, three manufacturers of generic clozapine have submitted abbreviated new drug applications to the US FDA for review and approval to market a generic clozapine product. In each case, the US FDA deemed the generic formulations to be bioequivalent to the brand name Clozaril®. Apart from case reports, industry-sponsored studies have been conducted comparing Clozaril® with two generic formulations. In one case, a generic formulation of clozapine manufactured by Creighton Products Corporation (formerly a subsidiary [generic house] of Sandoz Pharmaceuticals) was found to be bioequivalent to Clozaril®. On the other hand, studies (sponsored by Novartis) have challenged the bioequivalence, therapeutic equivalence and interchangeability between Clozaril® and a generic formulation manufactured by Zenith Goldline Pharmaceuticals (now IVAX Corporation). The IVAX Corporation-sponsored studies refuted these claims citing data from two patient registry database studies and one small clinical trial. Apart from a single in-house bioequivalence study, no further investigations have been conducted with a third generic formulation manufactured by Mylan Pharmaceutical.

Although the clinical significance of the above discrepancy is obvious, what is less than obvious is the pharmacoeconomic implications that arises from this debate. Clearly, if the brand name and generic formulations are ‘truly’ bioequivalent, then the cost savings realised would be the difference in acquisition cost. On the other hand, if the various formulations are not bioequivalent, then the economic benefits of a lower-priced generic formulation may be compromised. In the worst-case scenario, if a patient decompensates as a result of switching from Clozaril® to a generic formulation, the added direct costs (i.e. hospitalisation) and indirect cost (i.e. lost productivity) will most certainly offset any cost savings resulting from the use of a generic formulation. p ]Until further studies have been conducted, we suggest that patients who are treatment refractory and stabilised on Clozaril® are not switched to a generic formulation. On the other hand, if a patient is stabilised on Clozaril® and not treatment refractory, then cautious switching to a generic formulation may be reasonable. Finally, initiating a generic formulation in a ‘clozapine-naïve’ individual would be appropriate. The cost implications related to these recommendations will depend on the success or failure of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    Article  CAS  Google Scholar 

  2. Claghorn J, Honigfeld G, Abuzzahab Sr FS, et al. The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377–84

    Article  CAS  Google Scholar 

  3. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158 (3): 360–9

    Article  CAS  Google Scholar 

  4. Griffith RW, Saameli K. Clozapine and agranulocytosis. Lancet 1975; 2: 657

    Article  CAS  Google Scholar 

  5. de la Chapelle A, Kari C, Nurminen M, et al. Clozapine-induced agranulocytosis. Hum Genet 1977; 37: 183–94

    Article  Google Scholar 

  6. Idanpaan-Heikkila J, Alhava E, Olkinuora M, et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 193–8

    Article  CAS  Google Scholar 

  7. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992; 63: 51–70

    Article  CAS  Google Scholar 

  8. Umbricht SDG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55: 157–60

    PubMed  Google Scholar 

  9. Lieberman JA, Kane MJ, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329–38

    CAS  PubMed  Google Scholar 

  10. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079–81

    Article  CAS  Google Scholar 

  11. Dursun SM, Szemis A, Andrews H, et al. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24: 453–5

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999; 22: 98–101

    Article  CAS  Google Scholar 

  13. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2

    CAS  PubMed  Google Scholar 

  14. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81

    Article  CAS  Google Scholar 

  15. Office of Generic Drugs. US Food and Drug Administration website. Available from URL: http://www.fda.gov/cder/ogd/ [Accessed 2001 Nov 9]

  16. Food and Drug Administration. ZGP Clozapine, summary basis of approval, abbreviated new drug application. Rockville (MD): Food and Drug Administration, 1997 Nov 26

    Google Scholar 

  17. Miller Al, Maas JW, Contreras A, et al. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiatry 1993; 34: 178–87

    Article  CAS  Google Scholar 

  18. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine [letter]. Pharmacol Res 1994; 11: 1221

    Article  CAS  Google Scholar 

  19. Barbey JT. Single-dose bioequivalence investigation comparing Mylan clozapine tablets with Sandoz clozapine tablets. Washington, DC: Mylan Pharmaceuticals, 1999

    Google Scholar 

  20. Sramek JJ, Anand R, Hartman RD, et al. A bioequivalence study of brand and generic clozapine in patients with schizophrenia. Clin Drug Invest 1999; 17: 51–8

    Article  CAS  Google Scholar 

  21. Lam YWF, Ereshefsky L, Toney GB, et al. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001; 62 Suppl. 5: 18–22

    CAS  PubMed  Google Scholar 

  22. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomized switch of patients from Clozaril to generic clozapine. J Clin Psychiatry 2001; 62 Suppl. 5: 14–7

    CAS  PubMed  Google Scholar 

  23. Goldfinger SM, Silver MA, Henderson D, et al. Interchangeability of brand and generic clozapine. Available from URL: http://www.clozapineregistry.com/pdf/clozapine_poster.pdf. [Accessed 2001 Nov 21]

  24. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001; 35: 281–4

    Article  CAS  Google Scholar 

  25. Kumar V. Safety of clozapine (Zenith Goldline) in the management of geriatric patients. Int J Geriatric Psychopharmacology 1998; 1: 208–12

    CAS  Google Scholar 

  26. Data on file, FDA Center for Drug Evaluation and Research, Office of Generic Drugs, Rockville (MD), 1999 Mar 27

  27. Ereshefsky L, Lam YWF, Toney GB, et al. Clozapine bioequivalence in patients. In: New Research Program of the American Psychiatric Association; 2000 May 13–18; Chicago (IL); Abstract NR710: 749–50

  28. (BW)(FL-IVAX)(IVX)IVAX refutes Wall Street Journal article on clozapine. Available from URL: http://www.businesswire.com/webbox/bw.102500/202992990.htm 1–2. [Accessed 2001 Nov 9]

  29. Bender KJ. FDA confronts possible generic inequivalence. Psychiatric Times 2001 Feb; 18 (2). Available from URL: http://www.mhsource.com/pt/p010216.html [Accessed 2001 Nov 13]

    Google Scholar 

  30. Mofsen R, Balter J. Case reports of the re-emergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001; 23: 1720–31

    Article  CAS  Google Scholar 

  31. Kumar V. Use of atypical antipsychotic agents in geriatric patients: a review. Int J Geriatric Psychopharmacol 1997; 72: 15–23

    Google Scholar 

  32. Chengappa KN, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriat Psychiatr Neurol 1995; 8: 12–5

    CAS  Google Scholar 

  33. Frankenburg FR, Zanarini MC. Use of clozapine in nonschizophrenic patients. Harv Rev Psychiatry 1994; 2: 142–50

    Article  CAS  Google Scholar 

  34. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26–33

    Article  Google Scholar 

  35. Zenith Goldline Pharmaceuticals. Clozapine package insert. Maimi (FL): Zenith Goldline Pharmaceuticals, 1998

    Google Scholar 

  36. Procyshyn RM, Thompson D, Tse G. Pharmacoeconomics of clozapine, risperidone and olanzapine. CNS Drugs 2000; 13 (1): 47–76

    Article  CAS  Google Scholar 

  37. IMS Health. Risperdal vs. Zyprexa — a schizophrenic battle. Available from URL: www.ims-global.com/insight/news_story/0102/news_story_010202.htm [Accessed 2002 Sep 16]

  38. Rosack J. Pharmaceutical giants embroiled in generic-drug controversy. Psychiatric News; 2000 Dec. Available from URL: http://www.psych.org/pnews/00-12-15/giants.html [Accessed 2002 July 16]

    Google Scholar 

  39. Food and Drug Administration. Clozapine tablets: in vivo bioequivalence and in vitro dissolution testing (11/15/96). Rockville (MD): Food and Drug Administration, 1996

    Google Scholar 

Download references

Acknowledgements

We are grateful to Ms. Barbara Thompson, B.S. (Pharm.), the Manager of the Department of Pharmacy at Riverview Hospital, for her critical review of this manuscript. No sources of funding were used to assist in the preparation of this manuscript and the authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Riverview Hospital, 422 Henry Esson Young Building, 500 Lougheed Highway, V3C 4J2, Port Coquitlam, British Columbia, Canada

    Gordon Tse & Deborah Thompson

  2. Division of Research, Riverview Hospital, Port Coquitlam, British Columbia, Canada

    Ric M. Procyshyn

  3. Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada

    Ric M. Procyshyn

Authors
  1. Gordon Tse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ric M. Procyshyn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ric M. Procyshyn.

Additional information

Use of trade names is for product identification purposes only and does not imply endorsement.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tse, G., Thompson, D. & Procyshyn, R.M. Generic Clozapine. Pharmacoeconomics 21, 1–11 (2003). https://doi.org/10.2165/00019053-200321010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321010-00001

Keywords

Search

Navigation